AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01449006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
Study NCT02761343 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI scan
Description: Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
Study NCT00380731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy
Description: CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
Study NCT03350815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg open-label secukinumab
Description: All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.
Study NCT03350815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg double-blinded secukinumab
Description: Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)
Study NCT03350815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg double-blinded secukinumab
Description: Treatment Period 2 300 mg (2 s.c. injections of the 150 mg dose)
Study NCT04305366 — intervention group
Intervention type: OTHER
Intervention: Tissue collection
Description: Blood draw, Fine Needle Aspiration, Saliva Swab, Tumor/tissue sample
Study NCT05355662 — intervention group
Intervention type: OTHER
Intervention: Age
Description: The study was retrospective and did not involve the application of interventions.
Study NCT03818191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
Study NCT03818191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
Study NCT03274544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROLUNG
Description: Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~* Huang Qi (Radix Astragali Membranaceus): 2 g~* Dan Shen (Radix Salviae Miltiorrhizae): 1 g~* Jiang Huang (Rhizoma Curcumae Longae): 1 g~* Yin Xing (Semen Gingko Bilobae): 1 g~* Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~* Bai He (Bulbus Lilii): 1g~* Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~* Zi Su Ye (Folium Perillae Frutescentis): 1 g~* Yin Yang Huo (Herba Epimedii): 1g
Study NCT01181817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI and MRS
Description: fMRI and MRS
Study NCT00966615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double-chamber bag Stay-Safe Balance system
Description: 2-L exchange; three times a day
Study NCT00966615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucose-based dialysis solution
Description: 2-L exchange; three times a day
Study NCT02214290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
Study NCT02214290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
Study NCT02214290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: L-citrulline was used to examine the effect of the supplement on arterial function.
Study NCT03400475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: One topical application in peri-implant gingival crevice
Study NCT03400475 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One topical application in peri-implant gingival crevice
Study NCT00592904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
Study NCT00921843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone 0.1mg/kg
Description: Subjects will receive methadone as their intraoperative opioid.
Study NCT00921843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methadone 0.2mg/kg
Description: Subjects will receive methadone as their intraoperative opioid.
Study NCT00921843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone 0.2mg/kg
Description: Subjects will receive methadone as their intraoperative opioid.
Study NCT00921843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone 0.3mg/kg
Description: Subjects will receive methadone as their intraoperative opioid.
Study NCT00921843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects will not receive methadone as their intraoperative opioid.
Study NCT00398567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272
Description: HKI-272 by mouth
Study NCT00398567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter
Study NCT01961622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Florence D2A or similar closed loop glucose control system
Description: Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
Study NCT01961622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSII with real-time CGM
Description: Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
Study NCT03189160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-rhGH low dose
Description: PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
Study NCT03189160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-rhGH high dose
Description: PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
Study NCT03189160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-treatment control group
Study NCT01583855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation for atrial fibrillation, manual
Description: Ablation for atrial fibrillation will be performed manually
Study NCT01583855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation using Amigo remote catheter system
Description: Atrial fibrillation ablation will be performed using the Amigo remote catheter system
Study NCT03504059 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Long-term educational program
Description: Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
Study NCT03504059 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short-term educational program
Description: Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
Study NCT03077581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transevrsus abdominus plane block
Description: a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
Study NCT03077581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath block
Description: In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
Study NCT03077581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia infiltartion
Description: 40 mls of 0.255 bupivacaine will be infiltrated at skin incision
Study NCT00660153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (AV-951) plus FOLFOX6
Description: Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15.
Study NCT01338311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: 200mcg twice daily for a total of 7 doses
Study NCT01338311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mcg twice a day for a total of 7 doses (3.5 days).
Study NCT01476891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate MBSR
Description: Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
Study NCT01476891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control Group.
Description: Wait-list Control Group. The control group will receive the next available online MBSR program.
Study NCT02340234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
Study NCT00774774 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop
Study NCT01156194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathy 1
Description: Arnica montana C6 and Bellis perennis C6
Study NCT02340234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCS Cream
Description: TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
Study NCT02340234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCS Cream
Description: TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
Study NCT01156194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathy 2
Description: Arnica montana C30 and Bellis perennis C30
Study NCT01156194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: globule identical to true homeopathy comparators
Study NCT00774774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask
Description: Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~* during the night,~* when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended
Study NCT00891709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Description: First-in-man. Healthy volunteers
Study NCT00499603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
Study NCT00499603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Study NCT00499603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Study NCT00891709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 29102
Description: First-in-man. Healthy volunteers
Study NCT00348348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin
Description: Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
Study NCT00348348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin solution
Description: Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
Study NCT01859689 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Undergo image-guided HDR brachytherapy
Study NCT01859689 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Description: Undergo image-guided HDR brachytherapy
Study NCT01859689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00058097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT03242239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT02
Study NCT03242239 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-licensed Herceptin
Study NCT03242239 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Herceptin
Study NCT00058097 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT01005810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: 1200 mg twice daily for 8 weeks
Study NCT01005810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 capsules twice daily for 8 weeks
Study NCT01005810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
Study NCT02952170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI to assess hepatic steatosis
Study NCT01005810 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
Study NCT01103908 — intervention group
Intervention type: DEVICE
Intervention: HCE101 Cardiopulmonary Support Monitor
Description: Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
Study NCT04176068 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)
Description: Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
Study NCT00984646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study NCT00984646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study NCT00984646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study NCT00984646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study NCT00984646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study NCT00984646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study NCT00984646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study NCT00984646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar
Description: Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study NCT01555892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells: A
Description: Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
Study NCT01555892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells: B
Description: Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
Study NCT00984646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study NCT05771285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold application
Description: To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.
Study NCT02291705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectus sheath block
Description: ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
Study NCT02291705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: tramadol 1 mg/kg iv
Study NCT01659697 — intervention group
Intervention type: BEHAVIORAL
Intervention: intensive lifestyle counseling
Description: Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
Study NCT03486756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-CBT for anxiety-related asthma
Description: The specific assignments in the intervention will be based on individual behavior analysis for each participant.
Study NCT04102605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nunap Vision
Description: Participants receive visual perceptual training using the Nunap Vision software
Study NCT04102605 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nunap Vision-C
Description: Participants receive sham training using the Nunap Vision-C software
Study NCT00390338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: polarized dendritic cells
Study NCT00390338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-polarized dendritic cells
Study NCT04056325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Monotherapy, oral administration, single dose, fixed dose
Study NCT01864590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Pack
Description: Vacuum Pack Technique described by Barker et al.